{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:18:49Z","timestamp":1760300329442,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["Senior Fellowship Grant","Ref. TA.2011.40200.026"],"award-info":[{"award-number":["Senior Fellowship Grant","Ref. TA.2011.40200.026"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To evaluate the pharmacokinetic of plasma lopinavir (LPV) and ritonavir (RTV) when co-administered with three times weekly (TPW) rifabutin (RBT) at a dose of either 150 or 300\u00a0mg in African tuberculosis (TB) and HIV co-infected adult patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a pharmacokinetic study conducted in Ouagadougou among patients treated with a standard dosage of LPV\/RTV 400\/100\u00a0mg twice daily and RBT 150\u00a0mg TPW (arm A\u2009=\u20099 patients) or rifabutin 300\u00a0mg TPW (arm B\u2009=\u20097 patients) based regimens. Patients were recruited from the Bogodogo and Kossodo district hospitals in Ouagadougou from May 2013 to December 2015. Study inclusion criteria were that the patients were between 18 and 60\u00a0years of age, HIV-1 infected with pulmonary tuberculosis confirmed or suspected. Subsequent blood samples for pharmacokinetic monitoring were collected at 1, 2, 3, 4, 6, 8 and 12\u00a0h after combined drug ingestion for plasma drug monitoring using HPLC\/MS assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The medians LPV C<jats:sub>max<\/jats:sub>and T<jats:sub>max<\/jats:sub>were respectively, 20\u00a0\u03bcg\/mL and 4\u00a0h for the RBT 150\u00a0mg group (arm A) and 7.7\u00a0\u03bcg\/mL and 3\u00a0h for the RBT 300\u00a0mg group (arm B). The AUC<jats:sub>0\u201312<\/jats:sub>of LPV was 111.8\u00a0\u03bcg\u00a0h\/mL in patients belonging to arm A versus 69.9\u00a0\u03bcg\/mL for those in arm B (p\u2009=\u20090.313). The C<jats:sub>0<\/jats:sub>of LPV was lower than 4\u00a0\u03bcg\/mL in three patients receiving RBT 300\u00a0mg. Of note, the RTV plasma concentrations were nearly halved among patients on RBT 300\u00a0mg compared to those on lower RBT doses. The AUC<jats:sub>0\u201312<\/jats:sub>of RTV in arm A was 12.7\u00a0\u03bcg\u00a0h\/mL versus 6.6\u00a0\u03bcg\u00a0h\/ml in arm B (p\u2009=\u20090.313).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In our study, the pharmacokinetic of LPV and RTV was found to be highly variable when coadministrated with RBT 150\u00a0mg or 300\u00a0mg three times per week. There is a need for specific large study to verify clinical and virological effects of this variation, especially when coadministrated with RBT of 300\u00a0mg TPW, and to prevent viral resistance in response to under-dosing of LPV.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>PACTR201310000629390. Registered 28 October 2013,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.pactr.org\/\">http:\/\/www.pactr.org\/<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1186\/s12941-020-0345-6","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T10:03:59Z","timestamp":1579687439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis\u2013HIV co-infected African adult patients also receiving rifabutin 150 or 300\u00a0mg three times per week"],"prefix":"10.1186","volume":"19","clinical-trial-number":[{"clinical-trial-number":"pactr201310000629390","registry":"10.18810\/pactr"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-7530","authenticated-orcid":false,"given":"Henri Gautier","family":"Ouedraogo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Matteelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Sulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tegwinde Rebeca","family":"Compaore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Diagbouga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Tiendrebeogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Roggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadari","family":"Cisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Francesco","family":"Giorgetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Villani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lassana","family":"Sangare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Simpore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Regazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seni","family":"Kouanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"345_CR1","unstructured":"WHO. Tuberculosis and HIV. http:\/\/www.who.int\/hiv\/topics\/tb\/en\/. Accessed 26 May 2017."},{"key":"345_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1513\/pats.201010-064WR","volume":"8","author":"NA Martinson","year":"2011","unstructured":"Martinson NA, Hoffmann CJ, Chaisson RE. Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. Proc Am Thorac Soc. 2011;8:288\u201393. https:\/\/doi.org\/10.1513\/pats.201010-064WR.","journal-title":"Proc Am Thorac Soc"},{"key":"345_CR3","unstructured":"CDC. Managing drug interactions in the treatment of HIV-related tuberculosis. 2013. http:\/\/www.cdc.gov\/tb\/TB_HIV_Drugs\/default.htm. Accessed 19 Dec 2019."},{"key":"345_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-253","author":"SD Lawn","year":"2013","unstructured":"Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R. Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC Med. 2013. https:\/\/doi.org\/10.1186\/1741-7015-11-253.","journal-title":"BMC Med"},{"key":"345_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","volume":"53","author":"M Regazzi","year":"2014","unstructured":"Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug\u2013drug interactions with rifamycins. Clin Pharmacokinet. 2014;53:489\u2013507. https:\/\/doi.org\/10.1007\/s40262-014-0144-3.","journal-title":"Clin Pharmacokinet"},{"key":"345_CR6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/135965350501000413","volume":"10","author":"M Boffito","year":"2005","unstructured":"Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, et al. Therapeutic drug monitoring and drug\u2013drug interactions involving antiretroviral drugs. Antivir Ther. 2005;10:469\u201377.","journal-title":"Antivir Ther"},{"key":"345_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3851\/IMP2749","volume":"19","author":"RR Moholisa","year":"2014","unstructured":"Moholisa RR, Schomaker M, Kuhn L, Meredith S, Wiesner L, Coovadia A, et al. Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther. 2014;19:399\u2013406. https:\/\/doi.org\/10.3851\/IMP2749.","journal-title":"Antivir Ther"},{"key":"345_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2165\/00003088-199732030-00003","volume":"32","author":"M Barry","year":"1997","unstructured":"Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997;32:194\u2013209. https:\/\/doi.org\/10.2165\/00003088-199732030-00003.","journal-title":"Clin Pharmacokinet"},{"key":"345_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/01.ftd.0000245681.12092.d6","volume":"28","author":"MR van der Leur","year":"2006","unstructured":"van der Leur MR, Burger DM, la Porte CJL, Koopmans PP. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit. 2006;28:650\u20133. https:\/\/doi.org\/10.1097\/01.ftd.0000245681.12092.d6.","journal-title":"Ther Drug Monit"},{"key":"345_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1385\/1-59259-924-9:101","volume-title":"Drug Interactions in Infectious Diseases","author":"Kimberly A. Struble","year":"2005","unstructured":"Struble KA, Piscitelli SC, Rodvold KA. Drug interections with antiretrovirals for HIV infection. In: Drug interactions in infectious diseases. 2006. p. 101\u201336."},{"key":"345_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2165\/00003495-199447060-00008","volume":"47","author":"RN Brogden","year":"1994","unstructured":"Brogden RN, Fitton A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47:983\u20131009.","journal-title":"Drugs"},{"key":"345_CR12","unstructured":"pfizer. MYCOBUTIN_PM_F.pdf http:\/\/www.pfizer.ca\/sites\/g\/files\/g10028126\/f\/201511\/MYCOBUTIN_PM_F.pdf. Accessed 9 2017."},{"issue":"15","key":"345_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/2050-6511-15-61","volume":"19","author":"S Naiker","year":"2014","unstructured":"Naiker S, Connolly C, Wiesner L, Kellerman T, Reddy T, Harries A, et al. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV-infected tuberculosis patients on lopinavir\/ritonavir-based antiretroviral therapy. BMC Pharmacol Toxicol. 2014;19(15):61. https:\/\/doi.org\/10.1186\/2050-6511-15-61.","journal-title":"BMC Pharmacol Toxicol"},{"key":"345_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5588\/ijtld.10.0626","volume":"16","author":"A Loeliger","year":"2012","unstructured":"Loeliger A, Suthar AB, Ripin D, Glaziou P, O\u2019Brien M, Renaud-Thery F, et al. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? Int J Tuberc Lung Dis. 2012;16:6\u201315. https:\/\/doi.org\/10.5588\/ijtld.10.0626.","journal-title":"Int J Tuberc Lung Dis"},{"key":"345_CR15","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1093\/clinids\/22.Supplement_1.S15","volume":"22 Suppl 1","author":"TF Blaschke","year":"1996","unstructured":"Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis. 1996;22 Suppl 1:S15\u201321 (discussion S21\u201322).","journal-title":"Clin Infect Dis"},{"key":"345_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/2050-6511-15-61","volume":"15","author":"S Naiker","year":"2014","unstructured":"Naiker S, Connolly C, Wiesner L, Kellerman T, Reddy T, Harries A, et al. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV-infected tuberculosis patients on lopinavir\/ritonavir-based antiretroviral therapy. BMC Pharmacol Toxicol. 2014;15:61. https:\/\/doi.org\/10.1186\/2050-6511-15-61.","journal-title":"BMC Pharmacol Toxicol"},{"key":"345_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1086\/313771","volume":"30","author":"M Narita","year":"2000","unstructured":"Narita M, Stambaugh JJ, Hollender ES, Jones D, Pitchenik AE, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis. 2000;30:779\u201383. https:\/\/doi.org\/10.1086\/313771.","journal-title":"Clin Infect Dis"},{"key":"345_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/jac\/dkp263","volume":"64","author":"H Khachi","year":"2009","unstructured":"Khachi H, O\u2019Connell R, Ladenheim D, Orkin C. Pharmacokinetic interactions between rifabutin and lopinavir\/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother. 2009;64:871\u20133. https:\/\/doi.org\/10.1093\/jac\/dkp263.","journal-title":"J Antimicrob Chemother"},{"key":"345_CR19","doi-asserted-by":"publisher","first-page":"e70611","DOI":"10.1371\/journal.pone.0070611","volume":"8","author":"J Tanuma","year":"2013","unstructured":"Tanuma J, Sano K, Teruya K, Watanabe K, Aoki T, Honda H, et al. Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy. PLoS ONE. 2013;8:e70611. https:\/\/doi.org\/10.1371\/journal.pone.0070611.","journal-title":"PLoS ONE"},{"key":"345_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/jac\/dku382","volume":"70","author":"H Moultrie","year":"2015","unstructured":"Moultrie H, McIlleron H, Sawry S, Kellermann T, Wiesner L, Kindra G, et al. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir\/ritonavir. J Antimicrob Chemother. 2015;70:543\u20139. https:\/\/doi.org\/10.1093\/jac\/dku382.","journal-title":"J Antimicrob Chemother"},{"key":"345_CR21","doi-asserted-by":"publisher","first-page":"e84866","DOI":"10.1371\/journal.pone.0084866","volume":"9","author":"NTN Lan","year":"2014","unstructured":"Lan NTN, Thu NTN, Barrail-Tran A, Duc NH, Lan NN, Laureillard D, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir\/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS ONE. 2014;9:e84866. https:\/\/doi.org\/10.1371\/journal.pone.0084866.","journal-title":"PLoS ONE"},{"key":"345_CR22","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1128\/AAC.00315-13","volume":"57","author":"LF Lopez-Cortes","year":"2013","unstructured":"Lopez-Cortes LF, Ruiz-Valderas R, S\u00e1nchez-Rivas E, Lluch A, Gutierrez-Valencia A, Torres-Cornejo A, et al. lopinavir plasma concentrations and virological outcome with lopinavir\u2013ritonavir monotherapy in HIV-1-infected patients. Antimicrob Agents Chemother. 2013;57:3746\u201351. https:\/\/doi.org\/10.1128\/AAC.00315-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"56","key":"345_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/QAI.0b013e31820dc0cc","volume":"2011","author":"GU van Zyl","year":"1999","unstructured":"van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 1999;2011(56):333\u20139. https:\/\/doi.org\/10.1097\/QAI.0b013e31820dc0cc.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"345_CR24","unstructured":"La Porte CJL, Back D, Blaschke T, Boucher CAB, Fletcher CV, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. 2006:4\u201314."},{"key":"345_CR25","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1093\/jac\/dks218","volume":"67","author":"A Matteelli","year":"2012","unstructured":"Matteelli A, Villani P, Carvalho ACC, El-Hamad I, Cusato M, Apostoli A, et al. Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. J Antimicrob Chemother. 2012;67:2470\u20133. https:\/\/doi.org\/10.1093\/jac\/dks218.","journal-title":"J Antimicrob Chemother"},{"key":"345_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25333","author":"N Rockwood","year":"2019","unstructured":"Rockwood N, Cerrone M, Barber M, Hill AM, Pozniak AL. Global access of rifabutin for the treatment of tuberculosis\u2014why should we prioritize this? J Int AIDS Soc. 2019. https:\/\/doi.org\/10.1002\/jia2.25333.","journal-title":"J Int AIDS Soc"},{"key":"345_CR27","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/clinchem\/45.9.1465","volume":"45","author":"TP Moyer","year":"1999","unstructured":"Moyer TP, Temesgen Z, Enger R, Estes L, Charlson J, Oliver L, et al. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem. 1999;45:1465\u201376.","journal-title":"Clin Chem"},{"key":"345_CR28","unstructured":"EMEA. Guideline on bioanalytical method validation (EMEA\/CHMP\/EWP\/192217\/2009 Rev.1 Corr. 2**). 2011."},{"key":"345_CR29","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1097\/00002030-200406180-00009","volume":"18","author":"D Breilh","year":"2004","unstructured":"Breilh D, Pellegrin I, Rouz\u00e9s A, Berthoin K, Xuereb F, Budzinski H, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir\/ritonavir (KALEPHAR Study). AIDS. 2004;18:1305.","journal-title":"AIDS"},{"key":"345_CR30","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1086\/606056","volume":"49","author":"C Boulanger","year":"2009","unstructured":"Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir\u2013ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009;49:1305\u201311. https:\/\/doi.org\/10.1086\/606056.","journal-title":"Clin Infect Dis"},{"key":"345_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0300-2977(95)00099-2","volume":"48","author":"SH Lowe","year":"1996","unstructured":"Lowe SH, Kroon FP, Bollemeyer JG, Stricker BH, van\u2019t Wout JW. Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol. Neth J Med. 1996;48:211\u20135.","journal-title":"Neth J Med"},{"key":"345_CR32","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/sj.eye.6703016","volume":"21","author":"H-C Lin","year":"2007","unstructured":"Lin H-C, Lu P-L, Chang C-H. Uveitis associated with concurrent administration of rifabutin and lopinavir\/ritonavir (Kaletra). Eye. 2007;21:1540\u20131. https:\/\/doi.org\/10.1038\/sj.eye.6703016.","journal-title":"Eye"},{"key":"345_CR33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/07853890.2011.572905","volume":"43","author":"MW Hull","year":"2011","unstructured":"Hull MW, Montaner JSG. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med. 2011;43:375\u201388. https:\/\/doi.org\/10.3109\/07853890.2011.572905.","journal-title":"Ann Med"},{"key":"345_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40262-014-0167-9","volume":"53","author":"KB Larson","year":"2014","unstructured":"Larson KB, Wang K, Delille C, Otofokun I, Acosta EP. Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet. 2014;53:865\u201372. https:\/\/doi.org\/10.1007\/s40262-014-0167-9.","journal-title":"Clin Pharmacokinet"},{"key":"345_CR35","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1128\/AAC.41.3.654","volume":"41","author":"DJ Kempf","year":"1997","unstructured":"Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997;41:654\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"345_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2165\/00003088-200443050-00003","volume":"43","author":"JR King","year":"2004","unstructured":"King JR, Wynn H, Brundage R, Acosta EP. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet. 2004;43:291\u2013310. https:\/\/doi.org\/10.2165\/00003088-200443050-00003.","journal-title":"Clin Pharmacokinet"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-020-0345-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-020-0345-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-020-0345-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T09:34:59Z","timestamp":1665567299000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-020-0345-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["345"],"URL":"https:\/\/doi.org\/10.1186\/s12941-020-0345-6","relation":{},"ISSN":["1476-0711"],"issn-type":[{"type":"electronic","value":"1476-0711"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"5 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent. The study received ethical approval from the national Ethics Committee for Health Research (Comit\u00e9 d\u2019\u00e9thique pour la recherche en sant\u00e9, CERS) of Burkina Faso.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}